Literature DB >> 27062091

Comparison of Cancer Diagnoses Between the US Solid Organ Transplant Registry and Linked Central Cancer Registries.

E L Yanik1, L M Nogueira2, L Koch3, G Copeland4, C F Lynch5, K S Pawlish6, J L Finch7, A R Kahn8, B Y Hernandez9, D L Segev10, R M Pfeiffer1, J J Snyder11, B L Kasiske11, E A Engels1.   

Abstract

US transplant centers are required to report cancers in transplant recipients to the transplant network. The accuracy and completeness of these data, collected in the Scientific Registry of Transplant Recipients (SRTR), are unknown. We compared diagnoses in the SRTR and 15 linked cancer registries for colorectal, liver, lung, breast, prostate and kidney cancers; melanoma; and non-Hodgkin lymphoma (NHL). Among 187 384 transplants, 9323 cancers were documented in the SRTR or cancer registries. Only 36.8% of cancers were in both, with 47.5% and 15.7% of cases additionally documented solely in cancer registries or the SRTR, respectively. Agreement between the SRTR and cancer registries varied (kappa = 0.28 for liver cancer and kappa = 0.52-0.66 for lung, prostate, kidney, colorectum, and breast cancers). Upon evaluation, some NHLs documented only in cancer registries were identified in the SRTR as another type of posttransplant lymphoproliferative disorder. Some SRTR-only cases were explained by miscoding (colorectal cancer instead of anal cancer, metastases as lung or liver cancers) or missed matches with cancer registries, partly due to recipients' outmigration from catchment areas. Estimated sensitivity for identifying cancer was 52.5% for the SRTR and 84.3% for cancer registries. In conclusion, SRTR cancer data are substantially incomplete, limiting their usefulness for surveillance and research. © Copyright 2016 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Organ Procurement and Transplantation Network (OPTN); cancer/malignancy/neoplasia; clinical research/practice; health services and outcomes research; hematology/oncology

Mesh:

Year:  2016        PMID: 27062091      PMCID: PMC5055411          DOI: 10.1111/ajt.13818

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   9.369


  9 in total

1.  Hodgkin lymphoma among US solid organ transplant recipients.

Authors:  Scott C Quinlan; Ola Landgren; Lindsay M Morton; Eric A Engels
Journal:  Transplantation       Date:  2010-11-15       Impact factor: 4.939

2.  Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.

Authors:  H Myron Kauffman; Wida S Cherikh; Yulin Cheng; Douglas W Hanto; Barry D Kahan
Journal:  Transplantation       Date:  2005-10-15       Impact factor: 4.939

3.  Kaposi's sarcoma risk among transplant recipients in the United States (1993-2003).

Authors:  Sam M Mbulaiteye; Eric A Engels
Journal:  Int J Cancer       Date:  2006-12-01       Impact factor: 7.396

4.  What increased registry outreach may mean for cutaneous melanoma surveillance: impact of changes in Iowa.

Authors:  Mary E Charlton; Kiran Sapkota; Melody J Eide; Daniel B Olson; Kathleen McKeen; Charles E Platz; Jennifer A Schlichting; Charles F Lynch
Journal:  J Registry Manag       Date:  2014

5.  Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation.

Authors:  Christopher J Hoffmann; Aruna K Subramanian; Andrew M Cameron; Eric A Engels
Journal:  Transplantation       Date:  2008-09-27       Impact factor: 4.939

Review 6.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.

Authors:  Andrew E Grulich; Marina T van Leeuwen; Michael O Falster; Claire M Vajdic
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

7.  Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database.

Authors:  Marcelo Santos Sampaio; Yong W Cho; Yasir Qazi; Suphamai Bunnapradist; Ian V Hutchinson; Tariq Shah
Journal:  Transplantation       Date:  2012-11-27       Impact factor: 4.939

8.  Melanoma underreporting: why does it happen, how big is the problem, and how do we fix it?

Authors:  Myles Cockburn; Susan M Swetter; David Peng; Theresa H M Keegan; Dennis Deapen; Christina A Clarke
Journal:  J Am Acad Dermatol       Date:  2008-12       Impact factor: 11.527

9.  Spectrum of cancer risk among US solid organ transplant recipients.

Authors:  Eric A Engels; Ruth M Pfeiffer; Joseph F Fraumeni; Bertram L Kasiske; Ajay K Israni; Jon J Snyder; Robert A Wolfe; Nathan P Goodrich; A Rana Bayakly; Christina A Clarke; Glenn Copeland; Jack L Finch; Mary Lou Fleissner; Marc T Goodman; Amy Kahn; Lori Koch; Charles F Lynch; Margaret M Madeleine; Karen Pawlish; Chandrika Rao; Melanie A Williams; David Castenson; Michael Curry; Ruth Parsons; Gregory Fant; Monica Lin
Journal:  JAMA       Date:  2011-11-02       Impact factor: 157.335

  9 in total
  13 in total

Review 1.  Emerging Concepts in Managing Malignancy in Kidney Transplant Patients.

Authors:  Brittany Schreiber; Maen Abdelrahim; Ala Abudayyeh; Naoka Murakami
Journal:  Semin Nephrol       Date:  2022-01       Impact factor: 4.472

2.  Risk of Second Malignancies in Solid Organ Transplant Recipients Who Develop Keratinocyte Cancers.

Authors:  Rachel D Zamoiski; Elizabeth Yanik; Todd M Gibson; Elizabeth K Cahoon; Margaret M Madeleine; Charles F Lynch; Sally Gustafson; Marc T Goodman; Melissa Skeans; Ajay K Israni; Eric A Engels; Lindsay M Morton
Journal:  Cancer Res       Date:  2017-06-14       Impact factor: 13.312

3.  Contribution of solid organ transplant recipients to the pediatric non-hodgkin lymphoma burden in the United States.

Authors:  Elizabeth L Yanik; Meredith S Shiels; Jodi M Smith; Christina A Clarke; Charles F Lynch; Amy R Kahn; Lori Koch; Karen S Pawlish; Eric A Engels
Journal:  Cancer       Date:  2017-07-31       Impact factor: 6.921

4.  Cancer-related outcomes in kidney allograft recipients in England versus New York State: a comparative population-cohort analysis between 2003 and 2013.

Authors:  Francesca Jackson-Spence; Holly Gillott; Sanna Tahir; Jay Nath; Jemma Mytton; Felicity Evison; Adnan Sharif
Journal:  Cancer Med       Date:  2017-01-30       Impact factor: 4.452

5.  Mortality risk after cancer diagnosis in kidney transplant recipients: the limitations of analyzing hospital administration data alone.

Authors:  Francesca Jackson-Spence; Holly Gillott; Sanna Tahir; Jay Nath; Jemma Mytton; Felicity Evison; Adnan Sharif
Journal:  Cancer Med       Date:  2018-02-14       Impact factor: 4.452

6.  Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network.

Authors:  Ben Sprangers; Vinay Nair; Vincent Launay-Vacher; Leonardo V Riella; Kenar D Jhaveri
Journal:  Clin Kidney J       Date:  2017-10-27

Review 7.  Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months.

Authors:  Sebastian Wolf; Verena S Hoffmann; Antje Habicht; Teresa Kauke; Julian Bucher; Markus Schoenberg; Jens Werner; Markus Guba; Joachim Andrassy
Journal:  PLoS One       Date:  2018-04-16       Impact factor: 3.240

8.  Treatment for presumed BK polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States.

Authors:  Gaurav Gupta; Sarat Kuppachi; Roberto S Kalil; Christopher B Buck; Charles F Lynch; Eric A Engels
Journal:  Am J Transplant       Date:  2017-11-01       Impact factor: 9.369

9.  Outcomes of Organ Transplantation from Donors with a Cancer History.

Authors:  Shanzhou Huang; Yunhua Tang; Zebin Zhu; Jie Yang; Zhiheng Zhang; Linhe Wang; Chengjun Sun; Yixi Zhang; Qiang Zhao; Maogen Chen; Linwei Wu; Dongping Wang; Weiqiang Ju; Zhiyong Guo; Xiaoshun He
Journal:  Med Sci Monit       Date:  2018-02-18

10.  Effect of immunosuppression in miRNAs from extracellular vesicles of colorectal cancer and their influence on the pre-metastatic niche.

Authors:  Valeria Tubita; Joan Segui-Barber; Juan José Lozano; Elisenda Banon-Maneus; Jordi Rovira; David Cucchiari; Daniel Moya-Rull; Federico Oppenheimer; Hernando Del Portillo; Josep M Campistol; Fritz Diekmann; Maria José Ramirez-Bajo; Ignacio Revuelta
Journal:  Sci Rep       Date:  2019-08-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.